| Identification | Back Directory | [Name]
L-Phenylalanine, N-[(2R,3R)-3-methoxy-2-methyl-1-oxo-3-(2S)-2-pyrrolidinylpropyl]-, methyl ester, monohydrochloride (9CI) | [CAS]
864238-20-0 | [Synonyms]
MMAF intermediate 2
methyl ((2R,3R)-3-methoxy-2-methyl-3-((S)-pyrrolidin-2-yl)propanoyl)-L-phenylalaninate hydrochloride
(S)-methyl 2-((2R,3R)-3-methoxy-2-methyl-3-((S)-pyrrolidin-2-yl)propanamido)-3-phenylpropanoate hydrochloride
L-Phenylalanine, N-[(2R,3R)-3-methoxy-2-methyl-1-oxo-3-(2S)-2-pyrrolidinylpropyl]-, methyl ester, monohydrochloride (9CI) | [Molecular Formula]
C19H29ClN2O4 | [MDL Number]
MFCD28387092 | [MOL File]
864238-20-0.mol | [Molecular Weight]
384.898 |
| Hazard Information | Back Directory | [Uses]
MMAF intermediate 2 is an intermediate for the synthesis of MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1]. | [References]
[1] Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70. [Content Brief] DOI:10.1158/1078-0432.CCR-10-0017 |
|
|